Express Scripts: One of the Widest Moats in Health Care
Investors can pick up shares of this pharmacy benefit manager, which enjoys enormous supplier-pricing and scale advantages, at a significant discount.
Investors can pick up shares of this pharmacy benefit manager, which enjoys enormous supplier-pricing and scale advantages, at a significant discount.
Vishnu Lekraj: We recently conducted a competitive analysis of many health-care-services players, and one name that was very close to the top was Express Scripts (ESRX). When we couple this analysis with the firm's current market valuation, we believe it provides investors an opportunity to buy shares of a quality company at a significant discount. Express is the largest pharmacy benefit manager in the U.S., as it processes approximately 1.3 billion prescription claims annually, giving it about 22% market share.
PBMs help to manage a health insurance provider's drug benefits from construction of the plan to processing a prescription for a provider's member. The PBM industry is largely a "rational oligopoly," with Express leading the pack. CVS Health (CVS) and the new UnitedHealth/Catamaran PBM each process about 1 billion to 1.2 billion claims annually themselves, which gives three major players control over 65% of all prescriptions filled in the U.S. This dynamic endows these players--and especially Express Scripts--with enormous supplier-pricing and centralized-scale advantages.
With that said, I believe these players are some of the most competitively advantaged within the health-care ecosystem. Express trades at a material discount to our $100 fair value estimate, and this gives market participants the ability to own a high-quality business below its intrinsic value.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.